Dr. Arnold I. Chin, MD, PhD

Dr. Chin practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Chin's NPI, 1356578066, was assigned on June 19, 2009. Dr. Chin graduated from David Geffen School of Medicine at UCLA in 2003. Dr. Chin holds California license A89934.

Dr. Chin's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Chin's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Chin is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Urology. Dmand AI also links Dr. Chin to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chin practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Chin's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Chin is board certified in urology by the American Board of Urology. Dr. Chin is licensed in California.

Dmand AI lists bladder removal, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and kidney transplant among the conditions Dr. Chin treats.

CMS data shows 2,991 Medicare services from Dr. Chin across 15 procedure codes in 2024, for 407 Medicare patients. Medicare paid $109,433 for them.

CMS counts 407 Medicare patients who saw Dr. Chin in 2024. The largest group is 65 to 74, with 175 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chin's median patient age at 70, with 21% women.

In 2024, Dr. Chin wrote 507 Medicare Part D claims for 173 patients. 91% of them were for generic drugs. CMS names the drug for 388 of them, across 10 drugs with 11 or more claims each, at $28,128 in total drug cost. In 2023, CMS named 319 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Chin for performance year 2024, reported as part of a group. Dr. Chin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chin as offering telehealth. CMS counts 20 procedures of prostate resection by Dr. Chin, more than 81% of the clinicians it reports for that procedure.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 6 papers to Dr. Chin, published from 2010 to 2025. Dr. Chin's most frequent co-authors are Arie Belldegrun, MD, Jean Dekernion, MD and Miao Li, MD.

Dmand AI links Dr. Chin to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Urethral Neoplasms and Urethral Diseases.

CMS Open Payments shows 104 general payments to Dr. Chin from 13 drug and device companies from 2016 to 2025. Education make up the largest share, 42% of the total. Intuitive Surgical, Inc. paid the most, $31,679. It also lists 1 research payment totaling $570 in 2024.

Dr. Chin graduated from David Geffen School of Medicine at UCLA in 2003.

Dr. Chin is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.